Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone
New treatment approach improves survival for advanced bladder cancer patients before surgery
This randomized, phase III, open-label trial evaluated neoadjuvant and adjuvant durvalumab combined with gemcitabine and cisplatin versus ge…
Adding an immune drug to standard chemotherapy before bladder surgery helps patients stay cancer-free longer and live longer than older trea…
Neoadjuvant nivolumab alone or with ipilimumab in cisplatin-ineligible muscle-invasive bladder cancer
Hope for Bladder Cancer When Chemo Isn't an Option
This Phase II trial evaluated neoadjuvant nivolumab alone or with ipilimumab in 30 cisplatin-ineligible patients with muscle-invasive bladde…
Patients with advanced bladder cancer who can't take standard chemo may now qualify for surgery after a new immunotherapy treatment.
Targeted therapy versus non-targeted therapy in renal cell carcinoma patients
Real-world study in Taiwan shows targeted therapy offers similar life expectancy for advanced kidney cancer compared to non-targeted therapy
This real-world cohort study analyzed 14,131 renal cell carcinoma cases in Taiwan from 1998 to 2016.
In Taiwan, targeted therapy for advanced kidney cancer offers similar life expectancy to non-targeted therapy, with both groups living aroun…
Simlukafusp alfa plus atezolizumab with or without bevacizumab shows antitumor activity in metastatic renal cell carcinoma
Does adding bevacizumab nearly triple the time before kidney cancer grows back?
A phase Ib randomized open-label study in 66 patients with metastatic renal cell carcinoma found objective response rates of 25% with simluk…
Adding bevacizumab nearly tripled the time before kidney cancer grew back compared to a two-drug mix in this early study.
Predictors of pathological upstaging in clinical stage T1 renal cell carcinoma include male gender, age, and irregular margins
Could your kidney tumor look smaller than it really is inside?
This meta-analysis and systematic review evaluated 24,957 patients with clinical stage T1 renal cell carcinoma to identify predictors of pat…
A kidney tumor that looks small on a scan might actually be more advanced than doctors think, raising the risk of it returning after surgery…
Late Wilms tumor recurrence observed 32 years after diagnosis in a single case report
A Childhood Kidney Tumor Returned 32 Years Later
This systematic review analyzed a case report of a one-year-old female with bilateral, favorable-histology Wilms tumor.
Very late recurrence of childhood kidney cancer is extremely rare but possible, and this case reminds survivors and doctors that long-ago ca…
CFP10 immunohistochemistry shows high sensitivity for renal tuberculosis in surgical specimens
New Test Finds Hidden TB in Kidney Tissue
A retrospective cohort study of 86 patients with surgically resected renal tissue found CFP10 immunohistochemical staining had 91.8% sensiti…
A new kidney test spots hidden tuberculosis by finding a specific protein that standard methods often miss, helping doctors catch the infect…
Adjuvant intravesical BCG versus Epirubicin in intermediate-risk non-muscle invasive bladder cancer
A Common Bladder Cancer Treatment Extends Remission, But at a Cost
This randomized controlled trial compared adjuvant intravesical BCG and Epirubicin in 122 patients with intermediate-risk non-muscle invasiv…
For a common bladder cancer, one treatment keeps the disease away longer, but the other may offer a better daily life.
Meta-analysis shows ERAS care improves recovery and reduces complications in laparoscopic nephrectomy for renal cancer
ERAS Care Helps Kidney Cancer Patients Heal Faster
This meta-analysis evaluated enhanced recovery after surgery (ERAS) versus traditional care in 2,361 patients undergoing laparoscopic radica…
Kidney cancer patients recovering from surgery heal faster with a special plan, eating and walking sooner while spending less time in the ho…
Phase II trial finds adding gemcitabine to cisplatin-radiotherapy does not improve 2-year disease-free survival in muscle-invasive bladder cancer
Adding gemcitabine to cisplatin did not improve disease-free survival in bladder cancer patients
A Phase II randomized trial in 69 patients with pT2-pT3N0M0 muscle-invasive bladder cancer found similar 2-year disease-free survival (58.3%…
Adding gemcitabine to cisplatin radiotherapy did not improve disease-free survival for bladder cancer patients, with similar two-year rates …
Audit plus peer comparison improved documentation of tumour features and resection completeness in non-muscle-invasive bladder cancer surgery
Audit and feedback improved documentation of bladder cancer surgery details in a large trial
This cluster randomised controlled trial involved 14,915 patients undergoing transurethral resection of bladder tumour surgery across 201 si…
This large study examined whether adding peer comparison and education to standard audits changed how bladder cancer surgery was performed.
Neoadjuvant sacituzumab govitecan plus pembrolizumab shows 39% clinical complete response in MIBC
Drug combination shows promise for bladder cancer patients who cannot take standard chemotherapy
A single-arm phase 2 study of 49 patients with muscle-invasive bladder cancer ineligible for cisplatin found a clinical complete response ra…
A new drug combination helped 39% of bladder cancer patients who couldn't take standard chemotherapy achieve a complete response before surg…